

# Hepatitis B virus and hepatitis C virus in hemodialysis patients: A prevalence study from dialysis centers in El-Beyda and Almarj- Libya

## ABSTRACT

**Background:** Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections represent significant public health issues globally. These infection is a lead cause of morbidity and mortality among hemodialysis (HD) patients. Yet, little research has focused on the morbidity measures of these serious disorders in low and middle income countries.

**Aims:** The study aims to estimate the prevalence of hepatitis B and C among HD patients in El-Beyda and Almarj cities. All the patients who underwent hemodialysis from January 2013 to December 2016 were included in the study. Patients of all age groups were tested for HBsAg and anti-HCV antibodies by third regeneration linked immunoassay (ELISA).

**Results:** In overall, 645 patients by end of 2016, 360 males (55.8 %) and 285 females (44.2 %) hemodialysis HD patients attending were recruited. The majority of the patients were found to be >50 years of age (41.1%) followed by 31-40 years (22.5%) and thereafter in 41-50 years (18%) and lowest prevalence was observed in the age group of <20 years (8.1%). Seroconversion rates were (0.3%, 0.5%) for hepatitis B surface antigen and (1.24 %, 8.68%), for anti-HCV antibodies in El-Beyda and Almarj respectively. Patients on maintenance HD units in couple of cities have a high incidence and prevalence of HCV infection comparison to HBV infection. Additionally, patients on maintenance HD units in El-Beyda have a low levels of infection comparison to HD unit in Almarj.

**Conclusion:** Urgent action is required to improve infection control measures in HD centres and to reduce dependence practically on blood transfusions which consider main reasons for infection in both units.

**Keywords:** Hemodialysis (HD), Hepatitis B virus, Hepatitis C virus, El-Beyda, Almarj, Libya.

## 1. INTRODUCTION

The main function of the renal system is to maintain the body's state of homeostasis by carefully regulating fluid and electrolytes, removing wastes, and providing other functions [1]. Dysfunction of the kidneys is global health issue and may occur at any age and with varying degrees of severity [2]. Widespread access to dialysis has significantly increased survival in patients with chronic renal failure. Although using of this access can be efficient to treat renal failure, it may also lead to the transmission of some blood borne infections, such as HBV, HBC and HIV [3,4]. An estimated 400 million persons are carriers of HBV worldwide; 75% of whom reside in Asia and the Western Pacific, and HCV infection is estimated at approximately 170 million people globally [5].

There are high variation about prevalence and incidence of HCV infection in HD patients from country to country and ranges between 1 and 84.6% [6]. Libya provides free access to maintenance HD for end stage kidney disease through a rapidly expanding network of centres. Although there are no national dialysis practice guidelines or infection control polices enforced by health care authorities, there is general agreement that patients on HD should be screened for HBV and HCV infection before the initiation of HD and monitored every 3–6 months thereafter [7]. A national serological survey for HBV and HCV infections among the general population was performed in Libya during 2003 and revealed prevalence of 2.2% and 1.2% for HBV and HCV, respectively [8]. Other local surveys reported that the rate of HBsAg positivity among blood donors ranged from 1.3% to 4.6% [9], while the rate of HCV antibodies was 1.2% [10]. Very recently study in El-Beyda and Almarj reported that the frequency of HBsAg and HCV antibodies positive cases among blood donors were 0.21% and 0.24% respectively [11].

30 In case of hemodialysis patients, previous study conclude that patients on maintenance HD in Libya  
 31 have a high incidence and prevalence of HCV infection and lower rates of HBV infection [12]. However,  
 32 there are very few studies on the prevalence of such dual infections in HD patients from Northeast of  
 33 Libya. Therefore, the present study was undertaken to estimate the prevalence of HBV and HCV among  
 34 HD patients in El-Beyda and Almarj cities from 2013 till 2016.

35  
 36 **2. MATERIAL AND METHODS**  
 37

38 This descriptive study was carried out in HD units treating patients in El-Beyda and Almarj cities from  
 39 January 2013 to December 2016. These units in couple cities were only unites that received the majority  
 40 of patients in the littoral and outskirts regions which have a population of more than 500,000 inhabitants.  
 41 Data on the patient demographic characteristics, including their age, gender, area of residence, and  
 42 duration of dialysis treatment were gathered from patient files. Before dialysis began, all cases were  
 43 evaluated for HCV and HBV and considered positive if anti-HCV antibodies or HBs-Ag were detected.  
 44 Sero-positivity to HBV was defined by detection of hepatitis B surface antigen (HBs-Ag) and sero-  
 45 positivity to HCV by detection of anti-HCV antibodies by a third generation enzyme linked immunoassay  
 46 (ELISA). ELISA tests were performed in the hospital laboratory.  
 47

48 **3. RESULT**

49 This study carried out in the 4 consecutive years (January 2013-December 2016). A total number of  
 50 patients among years of study was found 78, 162, 177 and 228 in 2013, 2014, 2015 and 2016  
 51 respectively (Die cases were excused. New number of patients for each year was recorded without  
 52 patients from year before). A total number 645 patients (360 males, 285 females) were enrolled at both  
 53 haemodialysis units. Demographic patients' characteristics are presented in Tables 1 and 2. Prevalence  
 54 of patients was increased among a years of study from 78 in 2013 to 228 in 2016. Out of the total 645  
 55 patients, 55.8 % were males and 44.2 % were females. Highest prevalence was noted in age group of >  
 56 50 (41.1%). While, patients in the 31-40 years of age group were (22.5%), followed by 41-50 years of age  
 57 group (18%) and then followed by 21-30 years (10.2%). Lowest prevalence was observed in the age  
 58 group of <20 years (8.1%) (Table1). The geographical distribution was detailed in Table 2, the prevalence  
 59 patients was high in urban area 48 % comparison with rural area 36.8 %. It also prevalence of visitors  
 60 was increased during 2014 and 2015, most of them enrolled in Almarj's HD unit and all of them from  
 61 Benghazi city as a result of politic situation (Table 2). Table 3 was displayed the prevalence of hepatitis  
 62 among patients in each unit separately. When subjects were examined according to the presence of  
 63 hepatitis B, HBsAg positivity was detected in 0.3% (n = 2), 0.5% (n=3), and anti-HCV was positive in  
 64 1.24% (n=8), 8.68% (n=56) in HD unites in El-Beyda and Almarj respectively.  
 65

66 **Table 1.** Demographic characteristics among haemodialysis patients over 4 years.  
 67

AGE (YEARS)	2013		2014		2015		2016		%	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
< 20	1	3	6	8	5	8	10	11	3.4%	4.7%
21-30	2	2	11	9	10	6	15	11	5.9%	4.3%
31-40	14	8	21	15	23	15	27	22	13.2%	9.3%
41-50	6	6	15	12	18	16	24	20	9.8%	8.4%
> 50	21	15	39	26	42	34	50	38	23.6%	17.5%
<b>TOTAL</b>	<b>44</b>	<b>34</b>	<b>92</b>	<b>70</b>	<b>98</b>	<b>79</b>	<b>126</b>	<b>102</b>	<b>55.8%</b>	<b>44.2%</b>

68  
 69

70  
71

**Table 2:** The geographical distribution of haemodialysis patients in couple of cities.

PARAMETER	2013		2014		2015		2016		%	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
RURAL	19	15	22	27	29	34	51	40	18.8%	18%
URBAN	25	19	31	34	34	40	67	60	24.3%	23.7%
VISITOR	0	0	39	9	35	5	8	2	12.7%	2.5%

72  
73  
74

**Table 3:** Incidence of hepatitis B and hepatitis C among haemodialysis patients.

**EI-Beyda**

YEARS	HCV	HBV
2013	6	0
2014	0	1
2015	0	1
2016	2	0
%	1.24%	0.3%

75  
76

**Almarj**

YEARS	HCV	HBV
2013	1	0
2014	16	0
2015	37	1
2016	2	2
%	8.68%	0.5%

77

#### 4. DISCUSSION

Dysfunction kidney disease is now a global pandemic. In Libya has also increased exponentially in recent decades [13]. In this study carried out on HD unit in EI-Beyda and Almarj cities, we have shown the prevalence of patients was increased among years of study, it also shown the highest prevalence was noted in age group of > 50 (41.1%), and the lowest noted in age group of <20 (8.1%). This result similar to previous results have reported that, the prevalence rates were low in young adults and a steady increase with age peaking in the 55–64-year age group [7, 12]. Patients diagnosed with chronic renal failure on maintenance HD pose a higher risk for acquiring HBV or HCV infections due to frequent use of blood and blood products and multiple invasive procedures performed in kidney patients [14]. The literature review points to the fact that viral hepatitis is a serious threat for HD patients as 1.9% of all deaths among this population are related to the consequence of viral hepatitis [15]. The results from our study demonstrate that, the prevalence of HBsAg and HCV infections in HD patients were 0.3% & 1.24%, in EI-Beyda and 0.5% & 8.68% in Almarj respectively. This finding is similar to many studies that have reported in Arab countries, the prevalence of chronic HBV among HD patients ranged from 2.0 % in Morocco [16], to 11.8 % in Bahrain [17]. In Jordan, the prevalence of HBV was found to be 5.9 % [18]. Recently study among HD in India was also found the prevalence of HCV infection 1.5% and HBV 0.8% [19, 20]. In Egypt, only 1.1 % were infected with HBV and 9.3 % with HCV [21]. However our result was lower than other study in Middle East, the prevalence of HCV antibodies among HD patients has been reported to range from 27 % in Lebanon to 48.9 % in Syria [22]. Our results have also showed the prevalence of HCV was higher than HBV among HD patients. This agree with previous study conclude that patients on maintenance HD in Libya have a high incidence and prevalence of HCV infection and lower rates of HBV infection [12]. Since both of these viruses share a common mode of transmission, we looked for the occurrence of coinfections among the cases studied. Among present cases, dual infection with HBV was seen in two patients in EI-Beyda and three patients in Almarj, while HCV was seen in eight patients in EI-Beyda and fifty-six patients in Almarj. Most of them were visitors from Benghazi during 2014

103 & 2015, and they get long time of duration of dialysis. Patients with dual infection of HBV or HCV were  
104 also having history of transfusion of blood (Table 3). Duration of dialysis is an important risk factor for  
105 acquiring infections as it is related to nosocomial transmission and dissemination of the infections in the  
106 dialysis units [14]. Multiple transfusions is important factor contributing to the higher rates is the enhanced  
107 risk of coinfections among chronic renal failure patients on HD.  
108

## 109 **CONCLUSION AND RECOMMENDATION**

110 In conclusion, patients on maintenance HD in El-Beyda and Almarj cities have a high incidence and  
111 prevalence of HCV infection and lower rates of HBV infection. The factors associated with HBV and HCV  
112 infection are highly suggestive of nosocomial transmission within HD units. It is necessary take action to  
113 minimise level of infection and reduce the risk of hepatitis seroconversion in the both units. The data  
114 presented were obtained during the recent conflict in Libya. It is possible that disruption of services due to  
115 the conflict may have exacerbated the problem of hepatitis virus infection in HD patients.

## 116 **CONSENT**

117 It is not applicable.  
118

## 119 **ACKNOWLEDGEMENTS**

120 The authors would like to acknowledge the help and assistance of HD units in couple of  
121 regions.  
122

## 123 **COMPETING INTERESTS**

124 Authors have declared that no competing interests exist.  
125  
126

## 127 **REFERENCE:**

- 128 1. Kanda H, Hirasaki Y, Iida T, Kanao-Kanda M, Toyama Y and Kunisawa T. Effect of fluid  
129 loading on left ventricular volume and stroke volume variability in patients with end-stage  
130 renal disease: a pilot study. *Threptic Clinical Risk Managment*. 2015: 11:1619–1625.
- 131 2. Janice L and Kerry H. Brunner and Suddarath's textbook of medical surgical nursing. 2014:  
132 13<sup>th</sup> ed. p. 1507.
- 133 3. Saha D and Agarwal S. Hepatitis and HIV infection during haemodialysis. *Journal of Indian*  
134 *Medical Association*. 2001;99(4):194-213.
- 135 4. Mallamaci F, Tripepi G, Cutrupi S, Malatino L and Zoccali C. Prognostic value of combined  
136 use of biomarkers of inflammation, endothelial dysfunction, and myocardial pathology in patients  
137 with ESRD. *Kidney International*. 2005; 67(6): 2330 –2337.
- 138 5. Bini E and Perumalswami P. Hepatitis B virus infection among American patients with chronic  
139 hepatitis C virus infection: Prevalence, racial/ ethnic differences, and viral interactions.  
140 *Hepatology*. 2010; (51): 759–766.
- 141 6. Karoney M and Siika A. Hepatitis C virus (HCV) infection in Africa: A review. *The Pan African*  
142 *Medical Journal*. 2013:14-44.
- 143 7. Alashek W, McIntyre C and Taal M. Provision and quality of dialysis services in Libya.  
144 *Hemodialysis International*. 2011; 15(4):444–452.
- 145 8. Elzouki A, Esmeo M, Samod M, Abonaja A, Alagi B and Daw M. Prevalence of hepatitis B, C  
146 and HIV infection in Libya: a population-based nationwide seroepidemiological study. *Liver*  
147 *International*. 2006:20-26.
- 148 9. Elzouki A. Hepatitis B infection in Libya: The magnitude of the problem. *The Libyan Journal of*  
149 *Infectious Diseases*. 2008; 2(1):20–25.

- 150 10. Daw M, Elkaber M, Drah A, Werfalli M, Mihat A and Siala I. Prevalence of hepatitis C virus  
151 antibodies among different populations of relative and attributable risk. Saudi Medical  
152 Journal. 2002: 23(11):1356–1360
- 153 11. Qowaider S, Ali MS, Moftah SA and Kahald FA. Prevalence of HBV and HCV Infections  
154 among Blood Donors in Northeast Libya International Blood Research & Reviews. 2017:7(1):  
155 2321-7219.
- 156 12. Alashek W, McIntyre C and Taal M. Epidemiology and aetiology of dialysis-treated end-stage  
157 kidney disease in Libya. BMC Nephrology. 2012:13-33.
- 158 13. Goleg F, Kong N and Sahathevan R. Dialysis-treated end-stage kidney disease in Libya:  
159 epidemiology and risk factors. International Urology and Nephrology. 2014: 46(8):1581-1587.
- 160 14. Abumwais J and Idris O. Prevalence of hepatitis C, hepatitis B, and HIV infection among  
161 haemodialysis patients in Jenin District (Palestine). Iranian Journal of Virology. 2010:4:38–44.
- 162 15. Aghakhani A, Banifazl M, Eslamifar A, Ahmadi F and Ramezani A. Viral hepatitis and HIV  
163 infection in hemodialysis patients. Hepatitis Monthly. 2012:12: 463–464.
- 164 16. Boulaajaj K, Elomari Y, Elmaliki B, Madkouri B, Zaid D and Benchemsi N. Prevalence of  
165 hepatitis C, hepatitis B and HIV infection among haemodialysis patients in Ibn-Rochd  
166 University Hospital, Casablanca. Nephrology Threptic. 2005:1(5):274–284.
- 167 17. Almawi W, Qadi A, Tamim H, Ameen G, Bu-Ali A and Arrayid S. Seroprevalence of hepatitis  
168 C virus and hepatitis B virus among dialysis patients in Bahrain and Saudi Arabia. Transplant  
169 Proceedings. 2004:36(6):1824–1826.
- 170 18. Al Hijazat M and Ajlouni Y. Hepatitis B infection among patients receiving chronic  
171 hemodialysis at the royal medical services in Jordan. Saudi Journal of Kidney Disease and  
172 Transplantation. 2008:19(2):260–267.
- 173 19. Malhotra, R.; Soin, D.; Grover, P.; Galhotra, S.; Khutan, H. and Kaur, N. Hepatitis B virus and  
174 hepatitis C virus co-infection in hemodialysis patients: A retrospective study from a tertiary  
175 care hospital of North India. Journal of Natural Science, Biology and Medicine.2016: 7(1): 72–  
176 74.
- 177 20. Chandra, M.; Khaja, M. and Hussain, M. Prevalence of hepatitis B and hepatitis C viral  
178 infections in Indian patients with chronic renal failure. Intervirology.2004:47(6):374–376
- 179 21. Edris, A.; Nour, M.; Zedan, O.; Mansour, A.; Ghandour, A. and Omran, T. Seroprevalence  
180 and risk factors for hepatitis B and C virus infection in Damietta Governorate, Egypt. East  
181 Mediator Health Journal. 2014:20(10):605–613.
- 182 22. Fallahian F and Najafi A. Epidemiology of hepatitis C in the Middle East. Saudi Journal of  
183 Kidney Disease and Transplantation. 2011:22:1–9.
- 184